Table 5.
Antibiotics resistance pattern of extreme drug resistance, pan drug resistance, extended-spectrum beta-lactamase and multidrug resistance patients, and their corresponding minimal inhibitory concentration values as per CLSI
| n=23 | AMI (>32) | TOB (>8) | CFZ (>32) | NOR (>8) | CIP (>2) | GEN (>2) | COL (>4) | CHL (>18) | CFP (>16) | IMI (>16) | MER (>16) | CFT (>32) | ERT (>4) | TG (>2) | AMP (>16) | CXT (>32) | TR-SM (>8/152) | PC-TB (>64/4) | AM-CA (>16/8) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X-1 | S | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-2 | R | R | R | R | R | R | S | S | R | R | R | R | R | R | R | R | S | R | R |
| X-3 | R | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R |
| X-4 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-5 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-6 | R | R | R | R | R | R | S | R | R | R | R | R | R | I | R | R | R | R | R |
| X-7 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-8 | R | R | R | R | R | R | S | S | R | R | R | R | R | R | R | R | R | R | R |
| X-9 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | S | R | R |
| X-10 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-11 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-12 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-13 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-14 | R | R | R | R | R | S | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-15 | R | R | R | R | R | R | S | R | R | R | R | R | R | S | R | R | R | R | R |
| X-16 | R | R | R | R | R | S | S | R | R | R | R | R | R | R | R | R | R | R | R |
| X-17 | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| E-1 | R | R | R | R | R | R | S | S | R | S | S | R | S | S | R | S | R | S | R |
| E-2 | S | R | R | R | S | S | S | S | I | S | S | R | S | NT | R | R | R | S | R |
| E-3 | S | S | R | R | S | S | S | S | R | S | S | R | S | S | R | S | S | S | R |
| P-1 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| P-2 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| M-1 | S | R | R | R | R | R | S | S | R | R | R | R | R | R | R | R | R | R | R |
MIC value for colistin sensitivity is <1 for all sensitive patients except X-7 (<0.5); MIC value for amikacin sensitivity is <4 for all sensitive patients; MIC value for imipenem sensitivity is <0.5, for meropenem is <0.125 and for ertapenem is <0.125 for all sensitive patients; MIC value for tigecycline sensitivity is <1 and for intermediate is 2. MIC value for trimethoprim-sulfamethoxazole is <1/19 for all sensitive patients; MIC value for piperacillin-tazobactam is 16/4 for E-1 and 4/4 for E-2 and E-3; MIC value for cefepime intermediate sensitivity is 8; MIC vale for chloramphenicol sensitivity is <8; MIC values for resistance is mentioned adjacent to antibiotics headers. X: Extreme drug resistance, P: Pan drug resistance, M: Multidrug resistance, I: Intermediate resistance, NT: Not tested, MIC: Minimal inhibitory concentration; AMI: Amikacin; TOB: Tobramycin; CFZ: Cefazolin; NOR: Norfloxacin, CIP: Ciprofloxacin, GEN: Gentamicin, COL: Colistin, CFP: Cefepime, IMI: Imipenem, MER: Meropenem, CFT: Ceftriaxone, ERT: Ertapenem, TG: Tigecycline, CXT: Cefoxitin, AMP: Ampicillin, TR/SM: Trimethoprim/sulfamethoxazole, PC/TB: piperacillin/tazobactam, AM/CA: Amoxicillin/clavulanic acid, CLSI: Clinical & Laboratory Standards Institute